SUSTAIN-6
Definition
Cardiovascular outcomes for semaglutide in type 2 diabetes at high CV risk (Marso et al., NEJM 2016): a 26% relative reduction in three-point MACE. It confirmed what LEADER had signaled for the class.
GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature. Not one of them is an AI-generated summary.
Other terms under trial
Where the evidence lives
- SUSTAIN-6 trial deep-dive
- The full GLP-1 glossary (149 terms, 8 categories)
- Research articles — written from primary sources
- Tools and calculators
- Compare GLP-1 telehealth providers